Target- |
MechanismImmunostimulants |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
Reactogenicity, Safety and Immunogenicity of an Recombinant Universal Influenza Vaccine Uniflu in Healthy Volunteers From 18 to 60 Years Old
This is a single-site, randomized, double-blind, placebo-controlled study of Uniflu in fifty four (54) volunteers 18-60 years of age with a dose escalation.
All subjects will receive an intramuscular (IM) injection twice,with a 21 days interval between treatments.
100 Clinical Results associated with VA Pharma Limited Liability Company
0 Patents (Medical) associated with VA Pharma Limited Liability Company
100 Deals associated with VA Pharma Limited Liability Company
100 Translational Medicine associated with VA Pharma Limited Liability Company